共 39 条
- [31] TREATMENT WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANTAGONIST SB-75 DECREASES LEVELS OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS MESSENGER-RNA IN OV-1063 HUMAN EPITHELIAL OVARIAN-CANCER XENOGRAFTS IN NUDE-MICEINTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 5 (05) : 1031 - 1035SHIRAHIGE, YCOOK, CBPINSKI, JHALMOS, GNAIR, RSCHALLY, AV
- [32] The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialEUROPEAN JOURNAL OF CANCER, 2020, 134 : 99 - 106Dubsky, Peter C.Singer, Christian F.Egle, DanielWette, ViktorPetru, EdgarBalic, MarijaPichler, AngelikaGreil, RichardPetzer, Andreas L.Bago-Horvath, ZsuzsannaFesl, ChristianMeek, Stephanie M.Kronenwett, RalfRudas, MargarethaGnant, MichaelFilipits, Martin
- [33] Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in miceEUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 723 : 167 - 174Nakata, DaisukeMasaki, TsuneoTanaka, AkiraYoshimatsu, MieAkinaga, YumikoAsada, MariSasada, ReikoTakeyama, MichiyasuMiwa, KazuhiroWatanabe, TatsuyaKusaka, Masami
- [34] Involvement of an angiotensin II type 2 receptor (AT2R) signalling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in miceCANCER RESEARCH, 2014, 74 (19)Ishiguro, SusumuYoshimura, KiyoshiTakao, SonshinKawabata, AtsushiWall, TerrahnTsunedomi, RyouichiOka, MasaakiInui, MakotoPappas, CharalambosTzakos, Andreas G.Tamura, Masaaki
- [35] Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in miceCANCER BIOLOGY & THERAPY, 2015, 16 (02) : 307 - 316Ishiguro, SusumuYoshimura, KiyoshiTsunedomi, RyouichiOka, MasaakiTakao, SonshinInui, MakotoKawabata, AtsushiWall, TerrahnMagafa, VassilikiCordopatis, PaulTzakos, Andreas G.Tamura, Masaaki
- [37] Inhibitory effect of Z-360, a novel, orally active CCK-2/Gastrin receptor antagonist, on gastrin-17-induced proliferation, Pkb/Akt phosphorylation and in vivo growth of human pancreatic adenocarcinoma cell linesGASTROENTEROLOGY, 2007, 132 (04) : A433 - A434Emori, YutakaKawasaki, DaisukeEta, RunaIino, YukaHamano, HirokiYoshmaga, KojiTanaka, TakaoTakei, MineoWatsori, Susan A.
- [38] Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-AnalysisJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (10): : 3721 - 3730Wassenaar, M. J. E.Dekkers, O. M.Pereira, A. M.Wit, J. M.Smit, J. W.Biermasz, N. R.Romijn, J. A.
- [39] De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3046 - +Harbeck, NadiaGluz, OlegChristgen, MatthiasKates, Ronald ErnestBraun, MichaelKueemmel, SherkoSchumacher, ClaudiaPotenberg, JochemKraemer, StefanKleine-Tebbe, AnkeAugustin, DorisAktas, BahriyeForstbauer, HelmutTio, Jokevon Schumann, RaquelLiedtke, CorneliaGrischke, Eva-MariaSchumacher, JohannesWuerstlein, RachelKreipe, Hans HeinrichNitz, Ulrike Anneliese